Elusive Gamma-Secretase Identified

Model of an inhibitor targeted to g-secretase interacting with presenilin. The background shows an Alzheimer's brain that carried a presenilin mutation, with immunohistochemistry revealing abundant amyloid plaques (red-orange patches). For years researchers have been perplexed by the identity of g-secretase, an enzyme that cuts amyloid precursor protein (APP) into amyloid ß (Aß) fragments that form telltale plaques in the brains of Alzheimer's patients. Now researchers from Merck Rese

Written byNadia Halim
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share


Model of an inhibitor targeted to g-secretase interacting with presenilin. The background shows an Alzheimer's brain that carried a presenilin mutation, with immunohistochemistry revealing abundant amyloid plaques (red-orange patches).
For years researchers have been perplexed by the identity of g-secretase, an enzyme that cuts amyloid precursor protein (APP) into amyloid ß (Aß) fragments that form telltale plaques in the brains of Alzheimer's patients. Now researchers from Merck Research Laboratories and Harvard Medical School have independently solved the mystery, bringing the field one step closer to a therapeutic approach against Alzheimer's disease (AD). "All of the new and exciting information coming out is in agreement. It looks like presenilin is the long-sought g-secretase," says Dennis Selkoe, professor of neurology at Harvard Medical School.

Presenilin 1 (PS1) has been linked to AD since PS1 was first identified and cloned in 1995.1 PS1 mutations cause a rare form of early-onset familial AD. Bart ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies